{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:34:42Z","timestamp":1779147282309,"version":"3.51.4"},"reference-count":31,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder which can be life-threatening. AHA is due to autoantibodies against coagulation factor VIII. Disease onset may be idiopathic (approximately half of the cases) or triggered by autoimmune disorders, cancers, drugs, infections, or pregnancy. Besides treating the underlying disorder, specific AHA treatments include management of bleeding and inhibitor eradication. Various first-line and second-line hemostatic and immunosuppressive agents are currently available for the management of AHA. Recently, the hemostatic drug emicizumab and the immunosuppressive drug rituximab have been the object of intense research from investigators as innovative promising therapies for AHA. This narrative review will be focused on the current status of the clinical use of these two off-label therapeutic agents in AHA.<\/jats:p>","DOI":"10.1055\/s-0044-1779737","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T23:57:11Z","timestamp":1708732631000},"page":"068-072","source":"Crossref","is-referenced-by-count":12,"title":["Innovative Therapies for Acquired Hemophilia A"],"prefix":"10.1055","volume":"51","author":[{"given":"Massimo","family":"Franchini","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Focosi","sequence":"additional","affiliation":[{"name":"North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"issue":"06","key":"ref1","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/17474086.2020.1756259","article-title":"Advances in managing rare acquired bleeding disorders","volume":"13","author":"M Franchini","year":"2020","journal-title":"Expert Rev Hematol"},{"issue":"05","key":"ref2","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2006-06-029850","article-title":"Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation","volume":"109","author":"P W Collins","year":"2007","journal-title":"Blood"},{"issue":"04","key":"ref3","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1538-7836.2012.04654.x","article-title":"Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"10","author":"P Knoebl","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/MBC.0000000000000582","article-title":"Assessment of acquired hemophilia patient demographics in the United States: the Hemostasis and Thrombosis Research Society Registry","volume":"27","author":"C M Kessler","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"03","key":"ref5","first-page":"245","article-title":"Acquired haemophilia A: Italian Consensus Recommendations on diagnosis, general management and treatment of bleeding","volume":"20","author":"A Coppola","year":"2022","journal-title":"Blood Transfus"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00228-010-0852-z","article-title":"Acquired factor VIII haemophilia following influenza vaccination","volume":"66","author":"G Moulis","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"issue":"05","key":"ref7","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1365-2516.2011.02493.x","article-title":"A case of acquired haemophilia following H1N1 vaccination","volume":"17","author":"M T Pirrotta","year":"2011","journal-title":"Haemophilia"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.thromres.2022.12.010","article-title":"Association between SARS-CoV-2 infection or vaccination and acquired hemophilia A: a case report and literature update","volume":"222","author":"M Franchini","year":"2023","journal-title":"Thromb Res"},{"issue":"06","key":"ref9","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/pds.5615","article-title":"Cases of acquired hemophilia A following COVID-19 vaccines: cogent safety signal or possible reporting\/detection bias? Preliminary evidence from Tuscany, Italy","volume":"32","author":"G Roberto","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"07","key":"ref10","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood-2014-07-587089","article-title":"Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01\/2010 study","volume":"125","author":"A Tiede","year":"2015","journal-title":"Blood"},{"issue":"05","key":"ref11","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bjh.12829","article-title":"Inhibitor eradication with rituximab in haemophilia: where do we stand?","volume":"165","author":"M Franchini","year":"2014","journal-title":"Br J Haematol"},{"issue":"04","key":"ref12","first-page":"365","article-title":"Porcine recombinant factor VIII: an additional weapon to handle anti-factor VIII antibodies","volume":"15","author":"P M Mannucci","year":"2017","journal-title":"Blood Transfus"},{"issue":"07","key":"ref13","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"A Tiede","year":"2020","journal-title":"Haematologica"},{"issue":"03","key":"ref14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/17474086.2021.1892483","article-title":"Hemostatic therapy as a management strategy for acquired hemophilia: what does the future hold?","volume":"14","author":"M Franchini","year":"2021","journal-title":"Expert Rev Hematol"},{"issue":"09","key":"ref16","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1182\/blood-2002-03-0765","article-title":"Rituximab in the treatment of acquired factor VIII inhibitors","volume":"100","author":"A Wiestner","year":"2002","journal-title":"Blood"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.critrevonc.2006.11.004","article-title":"Rituximab in the treatment of adult acquired hemophilia A: a systematic review","volume":"63","author":"M Franchini","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"issue":"02","key":"ref18","first-page":"255","article-title":"The anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia A","volume":"14","author":"G D'arena","year":"2016","journal-title":"Blood Transfus"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2012-02-409185","article-title":"Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"120","author":"P Collins","year":"2012","journal-title":"Blood"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ajh.27128","article-title":"Single-dose rituximab plus glucocorticoid versus cyclophosphamide plus glucocorticoid in patients with newly diagnosed acquired hemophilia A: a multicenter, open-label, randomized noninferiority trial","volume":"99","author":"P Wang","year":"2024","journal-title":"Am J Hematol"},{"issue":"18","key":"ref22","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1182\/blood.2022016873","article-title":"Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen","volume":"140","author":"B Simon","year":"2022","journal-title":"Blood"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"e2020045","DOI":"10.4084\/mjhid.2020.045","article-title":"Acquired Haemophilia A: an intriguing disease","volume":"12","author":"M G Mazzucconi","year":"2020","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"03","key":"ref24","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/jth.15208","article-title":"Should emicizumab be used in patients with acquired hemophilia A?","volume":"19","author":"A Tiede","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.tmrv.2022.07.001","article-title":"Advances in acquired Hemophilia A","volume":"36","author":"J N Poston","year":"2022","journal-title":"Transfus Med Rev"},{"issue":"03","key":"ref26","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood.2020006315","article-title":"Emicizumab for the treatment of acquired hemophilia A","volume":"137","author":"P Knoebl","year":"2021","journal-title":"Blood"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/hae.14809","article-title":"Emicizumab for acquired haemophilia A: a case series","volume":"29","author":"M M Engelen","year":"2023","journal-title":"Haemophilia"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jtha.2022.10.004","article-title":"A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A","volume":"21","author":"M Shima","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/hae.14450","article-title":"Off-label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: a scoping review of the literature","volume":"28","author":"V M Thomas","year":"2022","journal-title":"Haemophilia"},{"issue":"11","key":"ref30","first-page":"002984","article-title":"Anticoagulation for stroke prevention after restoration of haemostasis with emicizumab in acquired haemophilia A","volume":"8","author":"K Al-Banaa","year":"2021","journal-title":"Eur J Case Rep Intern Med"},{"issue":"S 01","key":"ref31","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1182\/blood-2021-146147","article-title":"Evaluation of the safety of emicizumab prophylaxis in persons with hemophilia a: an updated summary of thrombotic events and thrombotic microangiopathies","volume":"138","author":"M Howard","year":"2021","journal-title":"Blood"},{"issue":"11","key":"ref32","doi-asserted-by":"crossref","first-page":"e913","DOI":"10.1016\/S2352-3026(23)00280-6","article-title":"Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study","volume":"10","author":"A Tiede","year":"2023","journal-title":"Lancet Haematol"},{"issue":"03","key":"ref33","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1182\/blood.2020008379","article-title":"Future directions in acquired hemophilia A","volume":"137","author":"S Siragusa","year":"2021","journal-title":"Blood"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1779737.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T23:37:58Z","timestamp":1737502678000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1779737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":31,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2025,1,21]]},"published-print":{"date-parts":[[2025,2]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1779737","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]}}}